A Democratic bill with 4 Democratic cosponsors · See all 4 cosponsors
Last activity — Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
The Prescription Drug Price Relief Act of 2025 aims to lower drug prices by ending government-granted monopolies for drugs priced higher than the median in other countries. The Secretary of Health and Human Services will review brand name drugs annually to determine if prices are excessive based on international price comparisons or other specific factors. If a drug is deemed excessively priced, the Secretary will waive its exclusivities and grant open, non-exclusive licenses to allow others to manufacture or import the drug. The bill also mandates that entities accepting these licenses pay a reasonable royalty to the patent holder. Additionally, the Act requires manufacturers to submit detailed annual reports regarding drug pricing, research costs, and revenues.
Yes· 3 of 8
- Scored +10
Does this lower the price of prescription medicines?
The bill specifically targets and aims to significantly lower the costs of brand name drugs through competition.
- Scored +8
Would households on low incomes be better off under this?
Lower drug prices provide significant relief to low-income households.
- Scored +7
Does this give people more protection from unfair business practices?
The bill enhances consumer protection by introducing competition to lower drug prices.
The opposite
- Scored -6
Does this make patent and copyright rules fairer?
The bill reduces exclusivity rights for patent holders to lower drug prices.
Who it would affect, and how
Potential Positive Impacts for People
-
Lower Prescription Drug Prices: The primary goal is to significantly lower prices for patients by ending monopolies on drugs that are priced higher than those in reference countries like Canada, the UK, Germany, France, and Japan (Section 2; Section 3).
-
Increased Competition: By granting open, non-exclusive licenses, the bill allows other people to make, use, sell, or import drugs, which introduces competition into the market (Section 3).
-
Faster Access to Generics: The Secretary is required to prioritize and act within 8 months of a generic drug or biosimilar application that references a drug with an open license (Section 3).
-
Accountability for Price Hikes: The Secretary can file civil actions to recover damages if a manufacturer increases the price of an excessively priced drug during the period before a competitor begins manufacturing under a license (Section 3).
-
Transparency of Information: The creation of a public database will provide information on drugs determined to have excessive prices, the number of licenses granted, and details regarding petitions and determinations (Section 5).
Potential Negative Impacts for People
-
Financial Burden on Patent Holders: Entities that accept open, non-exclusive licenses must pay a reasonable royalty to the patent holder (Section 4).
-
Potential for Civil Penalties on Manufacturers: Manufacturers face civil monetary penalties if they fail to submit required annual reporting information on time or provide false information (Section 6).
-
Litigation Risks: The Secretary has the authority to file civil actions against manufacturers to recover damages resulting from price increases on drugs determined to be excessively priced (Section 3).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Demographic And Interest Groups
- Would households on low incomes be better off under this? — Lower drug prices provide significant relief to low-income households. Would middle-income households be better off under this? — Lower prescription drug prices reduce the financial burden on middle-class families. Would retired people be better off under this? — Lower costs for prescription drugs are generally beneficial for retirees on fixed incomes.
- Healthcare
- Does this lower the price of prescription medicines? — The bill specifically targets and aims to significantly lower the costs of brand name drugs through competition. Does this make health care easier to get in general? — Lower drug prices can increase overall healthcare accessibility for the population.
- Governance And Ideology
- Does this give the federal government more power? — The bill expands the Secretary of HHS's authority to intervene in drug pricing and patent exclusivity. Does this make what the government does easier for the public to see? — The bill creates a public database for drug pricing and determination details.
- Economy And Finance
- Does this give people more protection from unfair business practices? — The bill enhances consumer protection by introducing competition to lower drug prices.
- Education And Technology
- Does this make patent and copyright rules fairer? — The bill reduces exclusivity rights for patent holders to lower drug prices.
- 7/22/2025
- 1 Cosponsor added.
- 6/3/2025
- 1 Cosponsor added.
- 5/23/2025
- 1 Cosponsor added.
- 5/21/2025
- Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 1 Cosponsor added.
- Introduced in House
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.
Yassamin AnsariDemocrat · Arizona
Pramila JayapalDemocrat · Washington
Ilhan OmarDemocrat · Minnesota
Janice SchakowskyDemocrat · Illinois